Conexeu Sciences Commences Trading on Nasdaq Under Ticker Symbol "CNXU"
Reno, Nevada--(Newsfile Corp. - May 21, 2026) - Conexeu Sciences Inc. (Nasdaq: CNXU) ("Conexeu" or the "Company"), a biotechnology company advancing tissue regeneration, announced it has officially commenced trading on the Nasdaq today under the ticker symbol "CNXU." The Company currently has 25,269,996 shares on an issued and outstanding basis and 35,238,222 shares on a fully diluted basis.
Healthcare and Hospitals, Pharmaceuticals, Health
2026-05-21 12:02 PM EDT | Conexeu Sciences Inc.
TMC Group Commissions New Capacity to Support Next-Generation Radiotheranostics
Vancouver, British Columbia--(Newsfile Corp. - May 21, 2026) - As demand for radiotheranostics continues to grow exponentially, TMC Group, a Canadian manufacturer of high-purity enriched stable isotopes, is commissioning new production lines this year. This will add 50 percent more capacity to help ensure reliable supply for radiopharmaceutical research, clinical development, and future commercialization. TMC Group will be exhibiting at the 2026 Society of Nuclear Medicine and Molecular
Technology, Biotechnology, Chemical, Pharmaceuticals
2026-05-21 10:00 AM EDT | TMC Group
Herbal Dispatch Completes Export of 261kg of Medical Cannabis to Europe
Vancouver, British Columbia--(Newsfile Corp. - May 21, 2026) - Herbal Dispatch Inc. (CSE: HERB) (OTCQB: LUFFF) (FSE: HA9) ("Herbal Dispatch" or the "Company"), a cannabis e-commerce and distribution platform, is pleased to announce the successful completion of a 261-kilogram international medical cannabis export shipment to Europe. The shipment represents another significant milestone in the continued expansion of Herbal Dispatch's international exp
Pharmaceuticals, Cannabis, Cannabis Dispensary
2026-05-21 5:01 AM EDT | Herbal Dispatch Inc.
Theralase(R) Closes C$4.8 Million Offering
Toronto, Ontario--(Newsfile Corp. - May 20, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses is pleased to announce that it has closed its previously announced brokered private placement offering ("Brokered Offering
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-05-20 11:06 AM EDT | Theralase Technologies Inc.
Sym Sciences Awarded $50,000 Grant to Advance IND-Ready Cannabinoid Research Platform
New York, New York--(Newsfile Corp. - May 20, 2026) - Sym Sciences announced today that it has been awarded a $50,000 grant from the to support the development of standardized, IND-ready cannabinoid materials for clinical research. The funding will enable Sym Sciences to expand its university research network and accelerate the preparation of regulatory-grade cannabinoid formulations designed for NIH-funded studies. The initiative is focused on streamlining the pathway from product deve
Healthcare and Hospitals, Pharmaceuticals, Health
2026-05-20 8:25 AM EDT | Sym Sciences
Optimi Health Announces Pricing of Oversubscribed US$15 Million Public Offering and Nasdaq Uplisting
Vancouver, British Columbia--(Newsfile Corp. - May 20, 2026) - Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) (the "Company" or "Optimi"), a commercial-stage pharmaceutical company focused on manufacturing and distributing finished psychedelic drug products, today announced the pricing of its underwritten public offering (the " Offering") in connection with the uplisting of its common shares to the Nasdaq Capital Market. The Company is offering 2,400,000 common shares at a public o
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-05-20 8:00 AM EDT | Optimi Health Corp.
Optimi Health gibt Preisfestsetzung für überzeichnetes öffentliches Angebot in Höhe von 15 Mio. US-$ und Nasdaq-Uplisting bekannt
Vancouver, British Columbia--(Newsfile Corp. - Mittwoch, 20. Mai 2026) - Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) (das "Unternehmen" oder "Optimi"), ein pharmazeutisches Unternehmen im kommerziellen Stadium mit Fokus auf die Herstellung und den Vertrieb fertiger psychedelischer Arzneimittelprodukte, gab heute die Preisfestsetzung seines gezeichneten öffentlichen Angebots (das "Angebot") im Zusammenhang mit dem Uplisting seiner Stammaktien an den Nasdaq Capital Market bek
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-05-20 8:00 AM EDT | Optimi Health Corp.
PreveCeutical Announces Extension of Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - May 19, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical"), is pleased to announce that, further to its news releases dated May 12, 2026 and April 22, 2026, it has extended the closing of its private non-brokered private placement (the "Offering") of units of the Company (each, a "Unit") to raise gross proceeds of $1,000,000 to June 12, 2026 and intend
Biotechnology, Pharmaceuticals, Health
2026-05-19 7:36 PM EDT | PreveCeutical Medical Inc.
Richards Group Inc. Announces May 2026 Dividend
Toronto, Ontario--(Newsfile Corp. - May 19, 2026) - Richards Group Inc. (TSX: RIC) (the "Company") announced today its cash dividend for the month ended May 31, 2026 of Cdn$0.11 per share. This dividend will be to shareholders of record at the close of business on May 29, 2026 and will be payable on June 12, 2026. Shareholders who are non-residents of Canada may be required to pay all withholding taxes payable in respect of any dividends of income by the Company, whether such dividends are
Healthcare and Hospitals, Household / Consumer / Cosmetics, Pharmaceuticals
2026-05-19 9:48 AM EDT | Richards Group Inc.
Maxwell Biosciences' Claromers Destroy Epstein-Barr
Austin, Texas--(Newsfile Corp. - May 19, 2026) - Maxwell Biosciences, a global health technology company pioneering a new category of immune-inspired, broad spectrum small molecules called Claromers®, today announces Claromers destroy Epstein-Barr virus, according to a third-party lab study.
Biotechnology, Pharmaceuticals
2026-05-19 9:00 AM EDT | Maxwell Biosciences, Inc.
Conexeu Sciences Advances 3D Biofabricated Matrix to Move Breast Reconstruction Beyond Implants
Reno, Nevada--(Newsfile Corp. - May 19, 2026) -
Healthcare and Hospitals, Pharmaceuticals, Health
2026-05-19 8:30 AM EDT | Conexeu Sciences Inc.
Neural Portfolio Company Hanf.com Expands German Retail Footprint with New Muhldorf am Inn Store and Four Refurbished Locations
Toronto, Ontario--(Newsfile Corp. - May 19, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic solutions for mental health conditions related to substance use disorders, together with its portfolio company CWE European Holdings Inc. ("CWE"), operating as Hanf.com, one of Germany's leading CBD retailers, is pleased to announce the opening of a new Hanf.
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-05-19 7:30 AM EDT | Neural Therapeutics Inc.
InMed Pharmaceuticals Amends Preferred Investment Options
Vancouver, British Columbia--(Newsfile Corp. - May 19, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announces that it has entered into an amending agreement with Armistice Capital Master Fund Ltd. ("Armistice") in respect of certain outstanding preferred investment options held b
Biotechnology, Pharmaceuticals
2026-05-19 6:00 AM EDT | InMed Pharmaceuticals
Herbal Dispatch Completes Company Record 500kg Medical Cannabis Export Shipment to Europe
Vancouver, British Columbia--(Newsfile Corp. - May 19, 2026) - Herbal Dispatch Inc. (CSE: HERB) (OTCQB: LUFFF) (FSE: HA9) ("Herbal Dispatch" or the "Company"), a cannabis e-commerce and distribution platform, is pleased to announce the successful completion of a 500-kilogram international medical cannabis export shipment to Europe. The shipment represents the largest international export shipment completed by Herbal Dispatch to date and marks
Pharmaceuticals, Cannabis, Cannabis Dispensary
2026-05-19 5:01 AM EDT | Herbal Dispatch Inc.
Defence Therapeutics Enhances In-House ADC Development Platform with Expanded Analytical and Cellular Testing Capabilities
Montreal, Quebec--(Newsfile Corp. - May 19, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce the expansion of internal capabilities to execute critical stages of its ACCUM®-enabled Antibody Drug Conjugates ("ADC") development pipeline. The Company has strengthened its purification, analytical characterization, conjugation
Biotechnology, Pharmaceuticals, Health
2026-05-19 3:15 AM EDT | Defence Therapeutics Inc.
Tate & Lyle Expands Collaboration with BioHarvest Sciences to Accelerate Next-Generation Sweetener Innovation
British Columbia and Rehovot, Israel--(Newsfile Corp. - May 18, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis™ technology and sustainable plant-based molecule development, today announced the expansion of its collaboration with Tate & Lyle PLC (Tate & Lyle), a global leader in ingredient solutions for healthier food and beverages, broadening the scope of their
Biotechnology, Pharmaceuticals, Health
2026-05-18 7:00 AM EDT | BioHarvest Sciences Inc.
Shuttle Pharmaceuticals and United Dogecoin Announce Purchase Order for up to 3,000 ElphaPex Dogecoin and Litecoin Mining Rigs
Gaithersburg, Maryland--(Newsfile Corp. - May 14, 2026) - Shuttle Pharmaceutical Holdings, Inc. (NASDAQ: SHPH) ("Shuttle" or the "Company") today announced the closing (the "Closing") of its previously announced merger with United Dogecoin Inc. ("United Dogecoin"), and the confirmation of a purchase order granting the Company the option to purchase up to 3,000 next-generation ElphaPex Scrypt mining rigs ("Mining Rigs") for use in the Company's Dogecoin (DOGE) and Litecoin (LTC) merge-mining o
2026-05-14 4:05 PM EDT | Shuttle Pharmaceuticals Holdings Inc.
Conexeu Sciences Unveils Defining Commitment: Architecting Bioregeneration(TM)
Reno, Nevada--(Newsfile Corp. - May 14, 2026) - Conexeu Sciences Inc. (the "Company" or "Conexeu") a medical device company advancing regenerative medicine through its patented bioregenerative extracellular matrix platform, today unveiled a new defining identity: Architecting Bioregeneration™.
Healthcare and Hospitals, Pharmaceuticals, Health
2026-05-14 8:30 AM EDT | Conexeu Sciences Inc.
Custom Health Announces Appointment of Chief Financial Officer and Board of Directors and Shareholder Approval for Proposed Public Listing
Jason Nalewany has been appointed as Chief Financial Officer of Custom Health and, following the completion of the Arrangement, the Resulting Issuer. Jason will support both companies by providing public company compliance, financial reporting, capital allocation and long-term growth strategy. The Resulting Issuer and the operations of Custom Health will be supported by an experienced Board of Directors that bring deep expertise across healthcare, technology, capital markets and
Technology, Pharmaceuticals, Health
2026-05-14 7:00 AM EDT | Custom Health Holdings Inc.
BioHarvest Sciences Reports First Quarter 2026 Financial Results and Provides Business Update
Quarterly revenue up 8% year over year; Annual revenue guidance range remains at $42-$48 million CDMO fragrance and Saffron projects reach successful milestones; First quarter CDMO revenue grew 135% YoY VINIA brand customer base grows to 90,000 active users as of the end of April Two-lens
Biotechnology, Pharmaceuticals, Health
2026-05-14 7:00 AM EDT | BioHarvest Sciences Inc.